한글목차

세계 오렉신 길항제 시장의 미래는 병원 및 클리닉 시장과 소매 약국 시장에서 기회가 있을 것으로 보입니다. 세계 오렉신 길항제 시장은 2025년부터 2031년까지 7.2%의 CAGR로 성장할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 수면 장애의 유병률 증가, 효과적인 불면증 치료에 대한 수요 증가, 오렉신 길항제에 대한 인식 증가 등입니다.

• Lucintel의 예측에 따르면, 유형별로는 듀얼 오렉신 수용체 길항제가 예측 기간 동안 높은 성장세를 보일 것으로 예상됩니다.
• 용도별로는 병원 및 진료소가 더 높은 성장이 예상됩니다.
• 지역별로는 북미가 예측 기간 동안 가장 높은 성장을 보일 것으로 예상됩니다.

오렉신 길항제 시장의 새로운 동향

오렉신 길항제 시장은 수면 생리학에 대한 지식 향상, 환자 요구의 변화, 혁신적인 의약품 개발 등 몇 가지 주요 트렌드에 힘입어 성장하고 있습니다. 이러한 추세는 제품 개발, 임상적 접근, 수면장애 치료에 대한 전반적인 접근 방식에 영향을 미치며, 보다 구체적이고 환자 중심의 치료로 변화하고 있습니다.

• 만성 불면증 치료 : 오렉신 길항제를 만성 불면증 치료제로 자리매김하는 경향은 분명하며, 단순히 진정시키는 것이 아니라 각성 증가의 근본적인 메커니즘을 치료할 수 있는 가능성을 강조하고 있습니다. 이 점을 강조함으로써 기존의 최면제와 차별화하여 보다 자연스러운 수면과 주간 기능 개선을 통한 장기적인 관리가 기대됩니다.
• 불면증 이외의 적응증 탐색 : 불면증 외에도 연구자들은 불안, 우울증, 약물 남용 등 오렉신계가 관여하는 다른 질환에 대한 오렉신 길항제 연구를 활발히 진행하고 있습니다. 이번 개발은 다른 정신질환 및 신경질환에 대한 시장 개척이 기대되며, 새로운 치료의 가능성을 열어줄 것으로 기대됩니다.
• 선택적 오렉신 수용체 길항제 개발 : 현재 이중 오렉신 수용체 길항제(DORA)가 주목받고 있으며, 선택적 오렉신 수용체 1(OX1R) 또는 오렉신 수용체 2(OX2R) 길항제의 개발도 계속되고 있습니다. 이러한 움직임은 치료 효과를 개선하고, 표적 외 부작용을 줄이면서 수면-각성 주기를 더 잘 조절할 수 있도록 하려는 시도입니다.
• 실제 근거중심으로 시장에 출시되는 오렉신 길항제의 수가 증가함에 따라, 대조군 임상시험을 넘어 다양한 환자군에서의 유효성과 안전성을 입증하는 실제 임상 증거 수집에 대한 관심이 높아지고 있습니다. 이러한 움직임은 처방 행동과 시장 진입에 대한 정보를 제공하고, 장기적인 환자 결과에 대한 지식을 넓히는 데 도움이 될 것입니다.
• 디지털 헬스 솔루션과의 통합 : 수면 모니터링 앱, 불면증 인지행동치료(CBT-I) 프로그램 등 디지털 헬스 솔루션에 오렉신 길항제 치료를 통합하는 새로운 움직임이 있습니다. 전인적 관행은 치료 순응도를 높이고, 수면 패턴을 추적하고, 환자를 철저하게 지원하도록 설계되었습니다.

이러한 추세는 오렉신 길항제 시장을 보다 진보되고 통합된 수면 웰니스 개념으로 변화시키고 있습니다. 만성질환에 대한 관심, 더 넓은 적응증, 개인화된 의료, 디지털화가 혁신을 일으키며 수면 질환의 치료 범위를 확장하고 있습니다.

오렉신 길항제 시장의 최근 동향

오렉신 길항제 시장은 수면의 신경생물학적 개선과 불면증에 대한 더 나은 치료법의 필요성에 힘입어 지속적인 발전을 거듭하고 있습니다. 최근 주요 동향은 치료의 폭을 넓히고, 환자의 이익을 높이고, 이러한 신약에 대한 접근성을 확대하는 데 중점을 두고 있는 것이 특징입니다.

• 신제품 승인 및 출시 가장 주목할 만한 진전은 주요 시장에서 새로운 이중 오렉신 수용체 길항제(DORA)의 승인 및 출시이며, 특히 달리덱산트(Quviviq)가 대표적입니다. 이로 인해 환자와 처방자에게 치료 옵션이 확대되고, 동종업계의 경쟁과 혁신이 더욱 치열해졌습니다.
• 주간 기능 개선 강조 : 새로운 오렉신 길항제의 최신 임상시험 및 출시 마케팅은 단순히 야간 수면뿐만 아니라 주간 기능 개선에 초점을 맞추고 있습니다. 이는 불면증이 환자의 일상 기능에 미치는 광범위한 영향을 인식하고 전반적으로 좋은 효과를 유도하는 치료 패러다임의 전환입니다.
• 장기 안전성 및 유효성 데이터 : 승인된 오렉신 길항제에 대해 보다 종합적인 장기 안전성 및 유효성 데이터가 제약회사에서 발표되고 있습니다. 이는 처방자와 환자의 신뢰도를 높이고, 만성적인 사용을 용이하게 하며, 일반적으로 의존성이나 금단증후군이 동반되는 기존의 최면제와는 차별화를 꾀할 수 있습니다.
• 다른 적응증에 대한 파이프라인 개발 : 불면증 이외의 불면증에 대한 오렉신 길항제의 치료 가능성을 밝히기 위한 연구가 진행 중입니다. 이번 개발은 불안장애, 우울증, 약물사용장애 등을 대상으로 한 임상시험이 진행 중이라는 점이 특징이며, 이는 시장의 전략적 다각화와 이들 화합물의 더 큰 치료 가능성을 반영하고 있습니다.
• 지리적 확장 및 시장 접근성 : 오렉신 길항제는 유럽과 아시아 주요 시장 등 더 많은 국가에서 판매 승인을 받아 시판되고 있습니다. 이러한 확장은 이러한 새로운 치료법에 대한 환자의 접근성을 높이고, 전 세계적으로 시장을 더욱 확대할 것입니다.

이러한 발전으로 인해 수면장애 치료 환경으로서 오렉신 길항제 시장은 보다 광범위하고 전 세계적으로 이용 가능한 시장으로 발전하고 있습니다. 신제품 출시, 주간 치료 성적 향상, 장기적인 증거, 광범위한 적응증으로 인해 오렉신 길항제는 현대 수면 의학의 기초가 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 거시경제 동향과 예측
• 업계 성장 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 오렉신 길항제 시장 : 종류별

• 개요
• 매력 분석 : 종류별
• 선택적 오렉신 수용체 길항제 : 동향과 예측(2019-2031년)
• 듀얼 오렉신 수용체 길항제 : 동향과 예측(2019-2031년)

제5장 세계의 오렉신 길항제 시장 : 용도별

• 개요
• 매력 분석 : 종류별
• 병원·클리닉 : 동향과 예측(2019-2031년)
• 소매 약국 : 동향과 예측(2019-2031년)
• 기타 : 동향과 예측(2019-2031년)

제6장 지역 분석

• 개요
• 세계의 오렉신 길항제 시장 : 지역별

제7장 북미의 오렉신 길항제 시장

• 개요
• 북미의 오렉신 길항제 시장 : 종류별
• 북미의 오렉신 길항제 시장 : 용도별
• 미국의 오렉신 길항제 시장
• 멕시코의 오렉신 길항제 시장
• 캐나다의 오렉신 길항제 시장

제8장 유럽의 오렉신 길항제 시장

• 개요
• 북미의 오렉신 길항제 시장 : 종류별
• 북미의 오렉신 길항제 시장 : 용도별
• 독일의 오렉신 길항제 시장
• 프랑스의 오렉신 길항제 시장
• 스페인의 오렉신 길항제 시장
• 이탈리아의 오렉신 길항제 시장
• 영국의 오렉신 길항제 시장

제9장 아시아태평양의 오렉신 길항제 시장

• 개요
• 아시아태평양의 오렉신 길항제 시장 : 종류별
• 아시아태평양의 오렉신 길항제 시장 : 용도별
• 일본의 오렉신 길항제 시장
• 인도의 오렉신 길항제 시장
• 중국의 오렉신 길항제 시장
• 한국의 오렉신 길항제 시장
• 인도네시아의 오렉신 길항제 시장

제10장 기타 지역(ROW)의 오렉신 길항제 시장

• 개요
• 기타 지역(ROW)의 오렉신 길항제 시장 : 종류별
• 기타 지역(ROW)의 오렉신 길항제 시장 : 용도별
• 중동의 오렉신 길항제 시장
• 남미의 오렉신 길항제 시장
• 아프리카의 오렉신 길항제 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업 간의 경쟁 관계
  • 구매자의 협상력
  • 공급업체의 협상력
  • 대체품의 위협
  • 신규 참여업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 성장 기회 : 종류별
  • 성장 기회 : 용도별
• 세계의 오렉신 길항제 시장 최신 동향
• 전략 분석
  • 신제품 개발
  • 인증·라이선싱
  • 기업 인수합병(M&A) , 계약, 제휴, 합작투자

제13장 밸류체인 위 주요 기업 개요

• 경쟁 분석
• Merck
• Eisai
• Idorsia
• Sun Pharmaceutical

제14장 부록

• 그림목차
• 표목차
• 분석 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• Lucintel에 대해
• 문의

영문목차

The future of the global orexin antagonist market looks promising with opportunities in the hospital & clinic and retail pharmacy markets. The global orexin antagonist market is expected to grow with a CAGR of 7.2% from 2025 to 2031. The major drivers for this market are the increasing prevalence of sleep disorders, the rising demand for effective insomnia treatment, and the growing awareness about orexin antagonists.

• Lucintel forecasts that, within the type category, dual orexin receptor antagonists are expected to witness higher growth over the forecast period.
• Within the application category, hospital & clinic is expected to witness higher growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Orexin Antagonist Market

The market for orexin antagonists is being addressed by some major trends that are being fueled by an enhanced knowledge of sleep physiology, changing patient requirements, and innovative drug development. These trends are impacting product development, clinical approaches, and the overall approach to the treatment of sleep disorders, changing towards more specific and patient-oriented therapies.

• Targeting Chronic Insomnia Disorder: There is a definite trend toward placing orexin antagonists as treatments for chronic insomnia disorder, highlighting their potential to treat the underlying mechanism of hyperarousal instead of simply sedating. This emphasis distinguishes them from older hypnotics, with the prospect of more natural sleep and better daytime functioning for long-term management.
• Exploration of Non-Insomnia Indications: In addition to insomnia, researchers are actively exploring orexin antagonists for other illnesses in which the orexin system is implicated, including anxiety, depression, and drug abuse. This development signals the promise for market expansion into other psychiatric and neurological disorders, opening up new therapeutic possibilities.
• Development of Selective Orexin Antagonists: Although dual orexin receptor antagonists (DORAs) are the current focus, efforts continue to develop selective orexin receptor 1 (OX1R) or orexin receptor 2 (OX2R) antagonists. This movement seeks to refine the therapeutic effects, perhaps providing more control over sleep-wake cycles with fewer off-target side effects.
• Real-World Evidence Emphasis: With increasing numbers of orexin antagonists making their way to the market, the spotlight has shifted towards gathering real-world evidence that proves their efficacy and safety in various patient populations beyond controlled clinical trials. This movement assists in informing prescribing behavior, market access, and broadens the knowledge of long-term patient outcomes.
• Integration with Digital Health Solutions: The trend in the market is a new trend of integrating orexin antagonist therapies into digital health solutions, including sleep monitoring apps and cognitive behavioral therapy for insomnia (CBT-I) programs. The holistic practice is designed to improve treatment compliance, track sleep patterns, and give thorough support to patients.

All these trends are together shaping the market for orexin antagonists into a more advanced and integrated concept of sleep wellness. Chronic illness focus, broader indications, individualized medicine, and digitization are creating innovation and expanding the therapeutic scope for sleep diseases.

Recent Developments in the Orexin Antagonist Market

The market for orexin antagonists is witnessing ongoing developments propelled by the improving neurobiology of sleep and the need for better treatments for insomnia. Recent major developments have been characterized by an emphasis on broadening the therapeutic armory, enhancing patient benefits, and widening access to these novel drugs.

• New Product Approvals and Launches: The most noteworthy evolution is the approval and launch of new dual orexin receptor antagonists (DORAs) in core markets, most notably daridorexant (Quviviq). This broadens the therapeutic choices for patients and prescribers, heightening competition and innovation in the class.
• Daytime Functioning Improvement Emphasis: The latest clinical trials and launch marketing for newer orexin antagonists increasingly focus on daytime functioning improvements, not merely nighttime sleep. This is a shift in treatment paradigm acknowledging the wider implications of insomnia for the daily functioning of patients and inducing overall good effects.
• Long-Term Safety and Efficacy Data: More comprehensive long-term safety and efficacy data are being published by pharmaceutical companies for approved orexin antagonists. This helps reinforce prescribers' and patients' confidence and facilitates chronic use, distinguishing the drugs from the older hypnotics that are generally linked with dependency or withdrawal syndrome.
• Pipeline Development for Other Indications: Studies are ongoing to reveal the therapeutic potential of orexin antagonists beyond insomnia. This development is characterized by ongoing clinical trials for conditions such as anxiety, depression, and substance use disorders, reflecting a strategic diversification of the market and greater therapeutic potential for these compounds.
• Geographic Expansion and Access to Markets: Orexin antagonists are increasingly receiving marketing approvals and becoming commercially available in additional countries, such as major markets in Europe and Asia. This expansion increases patient access to these new therapies and further expands the market globally.

These advancements are propelling the orexin antagonist market into a more extensive and world-available treatment environment for sleep disorders. New product launches, better daytime outcomes, long-term evidence, and broader indications are making orexin antagonists a foundation of contemporary sleep medicine.

Strategic Growth Opportunities in the Orexin Antagonist Market

The market for orexin antagonists offers substantial strategic growth potential through targeting specific patient segments and broadening therapeutic uses beyond primary insomnia. Strategically addressing these areas through development and marketing can open up new revenue opportunities and meet unmet medical needs.

• Chronic Insomnia Treatment: The most significant growth opportunity is to establish orexin antagonists as the first-line treatment of choice for chronic insomnia disorder. This includes widespread education of physicians and patients regarding their new mechanism of action, safe safety profile, and value for long-term sleep and daytime functioning.
• Insomnia with Comorbid Conditions: There is a significant opportunity in addressing insomnia that occurs with other medical or psychiatric illnesses, including depression, anxiety, or chronic pain. Orexin antagonists, with their potential to enhance sleep without sedative effects, present a compelling solution for these complicated patients.
• Sleep Maintenance Insomnia: Targeting specifically sleep maintenance insomnia (trouble staying asleep) reveals an important growth opportunity. Orexin antagonists, by suppressing wake drive during the night, are uniquely capable of enhancing sleep continuity, with an advantage over certain older hypnotics that act mainly on sleep onset.
• Substance Use Disorder and Sleep: Orexin antagonists have potential to treat sleep disturbances related to substance use disorders, possibly diminishing cravings and enhancing recovery rates. This is a strategic area of expansion that is meeting a major unmet need in the treatment of addiction, drawing on the orexin system's involvement in reward pathways.
• Geriatric Sleep Management: As the world's population ages, there's an increasing requirement for safe and effective sleep aids in the elderly, who are usually sensitive to the side effects of conventional hypnotics. Orexin antagonists, with their non-sedating action, present a good profile in this vulnerable population, representing a strategic growth opportunity.

These growth opportunities, which are key strategic drivers of the orexin antagonist market, are influencing the market by necessitating a more tailored and sophisticated approach to sleep disorder treatment. By targeting specialized patient populations and moving into comorbid conditions, the market is facing extensive growth and therapeutic diversification.

Orexin Antagonist Market Driver and Challenges

The orexin antagonist market is influenced by a sophisticated interplay of factors. These are the rising prevalence of sleep disorders, advances in neuroscience, and changing regulatory environments. Grasping these dynamics is important for everyone concerned, as they determine market growth, innovation, and patient access.

The factors responsible for driving the orexin antagonist market include:

1. Increasing Prevalence of Insomnia: The increasing prevalence of chronic insomnia globally, frequently attributed to contemporary lifestyles, stress, and aging populations, is a major driver. The widespread nature of this condition presents a large patient population in search of effective and acceptable sleep remedies.

2. Improved Safety Profile over Conventional Hypnotics: Orexin antagonists provide a differentiated safety profile with reduced risk of dependence, abuse, and next-day residual effects over benzodiazepines and Z-drugs. Improved safety motivates physician preference and patient compliance, driving market uptake.

3. Novel Mechanism of Action: The unique mechanism of action of orexin antagonists, selectively inhibiting wakefulness as opposed to sedating the brain broadly, is a strong motivator. Clinicians wanting more physiological sleep induction and patients who want rest to feel natural both find the targeted approach appealing.

4. Rising Awareness and Diagnosis of Sleep Disorders: Increased public and medical awareness of the health implications of chronic insomnia is resulting in higher diagnosis rates. This enhanced identification of the condition directly results in increased demand for effective prescribed medications such as orexin antagonists.

5. Positive Clinical Outcomes and Evidence: Strong clinical trial evidence of olanzapine-associated significant improvements in sleep onset, maintenance, and daytime functioning for approved orexin antagonists lends confidence. Such a sound therapeutic basis supports their global therapeutic implementation and reinforces the value of their therapy.

Challenges in the orexin antagonist market are:

1. High Price and Reimbursement Barriers: Orexin antagonists are newcomers and tend to be more expensive than generic established hypnotics, creating an access and reimbursement challenge. Payers often impose prior authorization or fail-first requirements, limiting utilization in cost-conscious healthcare systems.

2. Physician and Patient Education Requirements: Being a newer drug class, there is a high requirement for continued education for healthcare professionals and patients on the distinct mechanism of action, advantages, and correct usage of orexin antagonists. Overcoming resistance to change with previous prescribing patterns is a challenge.

3. Competition with Established and Generic Sleep Aids: The insomnia treatment market is saturated with long-standing and generic benzodiazepines, Z-drugs, and even over-the-counter products. Orexin antagonists have to constantly prove their higher value proposition to compete favorably with these easily accessible and frequently lower-cost products.

The market for orexin antagonists is heavily influenced by the increasing disease burden of insomnia, the positive safety profile of drugs, and their novel mechanism of action. High prices, requirement of intensive education, and competition with existing treatments are major challenges, and the market needs strategic pricing, transparent communication, and ongoing evidence generation to ensure long-term penetration.

List of Orexin Antagonist Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, orexin antagonist companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the orexin antagonist companies profiled in this report include:

• Merck
• Eisai
• Idorsia
• Sun Pharmaceutical

Orexin Antagonist Market by Segment

The study includes a forecast for the global orexin antagonist market by type, application, and region.

Orexin Antagonist Market by Type [Value from 2019 to 2031]:

• Selective Orexin Receptor Antagonist
• Dual Orexin Receptor Antagonist

Orexin Antagonist Market by Application [Value from 2019 to 2031]:

• Hospital & Clinic
• Retail Pharmacies
• Others

Orexin Antagonist Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Orexin Antagonist Market

The orexin antagonist market, a new generation of drugs chiefly for insomnia, is growing fast with its novel mechanism of action focused on wakefulness. Recent trends involve new drug approvals, widened geographic reach, and continued research into other therapeutic uses aside from sleep disorders, revolutionizing the way sleep and wakefulness are treated.

• United States: The US market has witnessed considerable adoption of approved dual orexin receptor antagonists such as suvorexant, lemborexant, and daridorexant. Developments center on augmenting physician and patient education, investigating real-world effectiveness, and navigating the arrival of generics as patents approach expiration, affecting market dynamics.
• China: China is a developing market with increasing awareness of insomnia as a public health issue. Recent advances include the approval of investigational new drug (IND) filings for DORAs, including daridorexant, via licensing arrangements with foreign firms. This reflects a move toward the introduction of new sleep therapies to the large Chinese population.
• Germany: Germany recently experienced the introduction and growing availability of dual orexin receptor antagonists such as daridorexant. Here, developments highlight the drug's unique mechanism of action, presenting an alternative method of treating insomnia to that of conventional hypnotics through enhanced sleep quality and functioning during the day.
• India: The Indian market for orexin antagonists is still in its infancy, with increased awareness of insomnia as a major health condition. Work is mainly centered on the investigation and evaluation of known orexin receptor antagonists, pending a possible future market entry when pharmaceutical firms evaluate the space for these new sleep therapies.
• Japan: Japan has actively embraced orexin antagonists, with the launch of lemborexant by Eisai and daridorexant by Nxera Pharma and Shionogi. Recent developments highlight the country's proactive approach to adopting new insomnia treatments, with a focus on improving sleep quality and addressing specific patient needs.

Features of the Global Orexin Antagonist Market

• Market Size Estimates: Orexin antagonist market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Orexin antagonist market size by type, application, and region in terms of value ($B).
• Regional Analysis: Orexin antagonist market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the orexin antagonist market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the orexin antagonist market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the orexin antagonist market by type (selective orexin receptor antagonist and dual orexin receptor antagonist), application (hospital & clinic, retail pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Orexin Antagonist Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Selective Orexin Receptor Antagonist: Trends and Forecast (2019-2031)
• 4.4 Dual Orexin Receptor Antagonist: Trends and Forecast (2019-2031)

5. Global Orexin Antagonist Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospital & Clinic: Trends and Forecast (2019-2031)
• 5.4 Retail Pharmacies: Trends and Forecast (2019-2031)
• 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Orexin Antagonist Market by Region

7. North American Orexin Antagonist Market

• 7.1 Overview
• 7.2 North American Orexin Antagonist Market by Type
• 7.3 North American Orexin Antagonist Market by Application
• 7.4 United States Orexin Antagonist Market
• 7.5 Mexican Orexin Antagonist Market
• 7.6 Canadian Orexin Antagonist Market

8. European Orexin Antagonist Market

• 8.1 Overview
• 8.2 European Orexin Antagonist Market by Type
• 8.3 European Orexin Antagonist Market by Application
• 8.4 German Orexin Antagonist Market
• 8.5 French Orexin Antagonist Market
• 8.6 Spanish Orexin Antagonist Market
• 8.7 Italian Orexin Antagonist Market
• 8.8 United Kingdom Orexin Antagonist Market

9. APAC Orexin Antagonist Market

• 9.1 Overview
• 9.2 APAC Orexin Antagonist Market by Type
• 9.3 APAC Orexin Antagonist Market by Application
• 9.4 Japanese Orexin Antagonist Market
• 9.5 Indian Orexin Antagonist Market
• 9.6 Chinese Orexin Antagonist Market
• 9.7 South Korean Orexin Antagonist Market
• 9.8 Indonesian Orexin Antagonist Market

10. ROW Orexin Antagonist Market

• 10.1 Overview
• 10.2 ROW Orexin Antagonist Market by Type
• 10.3 ROW Orexin Antagonist Market by Application
• 10.4 Middle Eastern Orexin Antagonist Market
• 10.5 South American Orexin Antagonist Market
• 10.6 African Orexin Antagonist Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Orexin Antagonist Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Merck
  • Company Overview
  • Orexin Antagonist Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Eisai
  • Company Overview
  • Orexin Antagonist Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Idorsia
  • Company Overview
  • Orexin Antagonist Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Sun Pharmaceutical
  • Company Overview
  • Orexin Antagonist Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us